Literature DB >> 19333724

Current immunological approaches for management of allergic rhinitis and bronchial asthma.

Deepsikha Srivastava1, Naveen Arora, Bhanu Pratap Singh.   

Abstract

A large population world over is affected with allergic diseases and asthma. Pharmacotherapy for allergic diseases and asthma is effective in controlling symptoms but on discontinuation of medication, symptoms reoccur. In contrast, immunotherapy modifies and corrects the underlying pathological immune responses in an antigen-specific manner. Immunotherapy shows an increase in IgG (blocking antibody) that competes with IgE for allergen, inhibiting the release of inflammatory mediators. Recent studies suggest that immunotherapy acts by modifying CD4+ T-cell responses either by immune deviation, T-cell anergy and/or both. Current immunological approaches for management of allergies and asthma involve immunization with native allergen, modified allergen, peptides/cDNA of allergen, anti-IgE, adjuvants coupled allergen, including immunostimulatory DNA sequences, cytokines, and bacterial products. These approaches modulate the immune response and are intended to give long-term benefit.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19333724     DOI: 10.1007/s00011-009-0033-7

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  154 in total

1.  Omalizumab treatment downregulates dendritic cell FcepsilonRI expression.

Authors:  Calman Prussin; Daniel T Griffith; Kevin M Boesel; Henry Lin; Barbara Foster; Thomas B Casale
Journal:  J Allergy Clin Immunol       Date:  2003-12       Impact factor: 10.793

2.  Recombinant glutathione-S-transferase a major allergen from Alternaria alternata for clinical use in allergy patients.

Authors:  Jay Shankar; Bhanu P Singh; Shailendra N Gaur; Naveen Arora
Journal:  Mol Immunol       Date:  2006-01-23       Impact factor: 4.407

3.  Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation.

Authors:  R J van Neerven; T Wikborg; G Lund; B Jacobsen; A Brinch-Nielsen; J Arnved; H Ipsen
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

4.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

Authors:  Christian Möller; Sten Dreborg; Hosne A Ferdousi; Susanne Halken; Arne Høst; Lars Jacobsen; Antti Koivikko; Dieter Y Koller; Bodo Niggemann; Lene A Norberg; Radvan Urbanek; Erkka Valovirta; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

Review 5.  Mechanisms of allergen-specific immunotherapy.

Authors:  Mübeccel Akdis; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2007-02-26       Impact factor: 10.793

6.  Purification and characterization of a major cross-reactive allergen from Epicoccum purpurascens.

Authors:  Vandana Bisht; Naveen Arora; B P Singh; S N Gaur; Susheela Sridhara
Journal:  Int Arch Allergy Immunol       Date:  2004-02-16       Impact factor: 2.749

7.  Life-threatening fish allergy successfully treated with immunotherapy.

Authors:  G Casimir; P Cuvelier; S Allard; J Duchateau
Journal:  Pediatr Allergy Immunol       Date:  1997-05       Impact factor: 6.377

8.  Coexpression of TGF-beta1 and IL-10 enables regulatory T cells to completely suppress airway hyperreactivity.

Authors:  Katrin Presser; Dorothee Schwinge; Michael Wegmann; Samuel Huber; Steffen Schmitt; Alexander Quaas; Joachim H Maxeiner; Susetta Finotto; Ansgar W Lohse; Manfred Blessing; Christoph Schramm
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

Review 9.  Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2007.

Authors:  Scott H Sicherer; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2008-03-05       Impact factor: 10.793

10.  Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

Authors:  Gabrielle Pauli; Tina H Larsen; Sabina Rak; Friedrich Horak; Elide Pastorello; Rudolf Valenta; Rudolph Valenta; Ashok Purohit; Monica Arvidsson; Alexander Kavina; Jan W Schroeder; Nadine Mothes; Susanne Spitzauer; Armelle Montagut; Sylvie Galvain; Michel Melac; Claude André; Lars K Poulsen; Hans-Jorgen Malling
Journal:  J Allergy Clin Immunol       Date:  2008-11       Impact factor: 10.793

View more
  1 in total

1.  In silico identification of IgE-binding epitopes of osmotin protein.

Authors:  Prerna Sharma; Shailendra Nath Gaur; Naveen Arora
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.